Hexima Limited is pleased to announce the appointment of Mr Michael Aldridge as Chief Business Officer and a member of the Board of Directors, effective 21 May 2019. Mr Aldridge will be based in San Francisco, focussing on business development and establishing Hexima’s presence in the US.

Chairman Professor Jonathan West said “I welcome Michael and his wealth of experience in leading early stage biotechnology companies, in particular his experience with Peplin Inc., where he took an Australian developed technology through clinical trials in the US and ultimately to a major acquisition.”

View full announcement (pdf)